Abstract IntroductionThe aim of this study was to assess the impact of baseline characteristics on visual outcome of patients with diabetic macular edema and compare the results of clinical trials with different patient populations. MethodsA model was created with patient-level data from the RESPOND/RESTORE trials to estimate the impact of baseline characteristics on increases in best-corrected visual acuity (BCVA) with anti-vascular endothelial growth factor therapies, measured by letters gained on the Early Treatment Diabetic Retinopathy Study scale from baseline to month 12. Mean BCVA gains with ranibizumab 0.5 mg pro re nata or laser photocoagulation monotherapy were predicted, assuming baseline characteristics equivalent to those in the VIVID-DME/VISTA-DME trials. These results were compared with the gain with aflibercept 2.0 mg every 8 weeks in VIVID-DME/VISTA-DME. Sensitivity analyses assessed outcome robustness. ResultsBaseline BCVA and central retinal thickness differed significantly between trials. In unadjusted data, patients in RESPOND/RESTORE receiving ranibizumab gained an additional 6.6 letters [95% confidence interval (CI): 4.5–8.7] compared with patients receiving laser monotherapy. After adjusting data to assume baseline characteristics equivalent to VIVID-DME/VISTA-DME, patients receiving ranibizumab were predicted to gain an additional 9.9 letters (95% CI: 7.3–12.4) compared with those receiving laser monotherapy. These results were similar (0.1-letter difference in favor of aflibercept; 95% CI: −2.9 to 3.2; P = 0.94) to the gain in BCVA in patients receiving aflibercept in VIVID-DME/VISTA-DME compared with those receiving laser monotherapy (10.0 letters, 95% CI: 8.3–11.7). ConclusionAfter adjusting for baseline characteristics, the difference in letters gained between patients receiving ranibizumab versus aflibercept was non-significant across trials, highlighting the importance of adjusting for baseline characteristics in future comparisons. FundingNovartis Pharma AG.
diabetic macular edema0.999999999998181^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/diabetic_retinopathy  

CI                            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

CI                            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

CI                            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

laser                         0.9999999998622116^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Laser                 

laser                         0.9999999998622116^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Laser                 

clinical trials               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Clinical_trial        

laser photocoagulation        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Laser_coagulation     

aflibercept                   0.999999999727379^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aflibercept           

95% CI                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

monotherapy                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Combination_therapy   

endothelial                   0.999999999960437^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Endothelium           

retinal                       0.9999961303683286^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Retina                

monotherapy                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Combination_therapy   

monotherapy                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Combination_therapy   

nata                          0.9644648032677645^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Nata,_Botswana        

confidence interval           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

aflibercept                   0.999999999727379^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aflibercept           

AG                            0.8440538758004886^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Aktiengesellschaft    

laser                         0.9999999998622116^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Laser                 

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

monotherapy                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Combination_therapy   

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

aflibercept                   0.999999999727379^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aflibercept           

aflibercept                   0.999999999727379^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aflibercept           

